During the disease course, most Inflammatory Bowel Disease patients present a condition of
malnutrition, undernutrition, or even overnutrition. These conditions are mainly due to …

The altered magnesium status in inflammatory bowel disease (IBD) patients may have a
significant clinical imprint considering its role in cell signaling and genomic stability, as well …

Background Ustekinumab was recently approved for the treatment of moderate to severe
Crohn's disease (CD). Although the ustekinumab Clinical Decision Support Tool (UST …

Tacrolimus therapy for ulcerative colitis is ineffective in certain patients; these patients
require biologics or colectomy. We examined the ability of serum albumin levels and …

Background Although the clinical efficacy of tofacitinib in patients with ulcerative colitis (UC)
has been assessed in the OCTAVE trial, there is a lack of adequate data on its efficacy in …

BACKGROUND Oral tacrolimus is a therapeutic agent for moderate to severe steroid-
dependent or resistant ulcerative colitis (UC), but remission induction is difficult, and it is …

Objective To explore the association between the controlling nutritional status (CONUT)
score and disease activity in patients with ulcerative colitis (UC). Methods This retrospective …

Anti-tumor necrosis factor (TNF)-α antibodies, including infliximab (IFX), adalimumab (ADA),
and golimumab, which were the first biologic therapeutic agents, have a crucial position in …

Advanced therapies for patients with mild-to-severe ulcerative colitis (UC) may result in
treatment failure. We examined whether the lymphocyte-to-monocyte ratio (L/M ratio) could …

Abstract Background and Aims Existing findings on outcomes of anti-tumor-necrosis-factor
(TNF) therapy in patients with inflammatory bowel diseases (IBD) are largely based on …